

Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study

Le Min¹, Frank Stephen Hodi², Anita Giobbie-Hurder², Patrick A. Ott², Jason J. Luke^{2,3}, Hilary Donahue², Meredith Davis², Rona S. Carroll¹, and Ursula B. Kaiser¹

Abstract

Purpose: To examine the onset and outcome of ipilimumab-related hypophysitis and the response to treatment with systemic high-dose corticosteroids (HDS).

Experimental Design: Twenty-five patients who developed ipilimumab-related hypophysitis were analyzed for the incidence, time to onset, time to resolution, frequency of resolution, and the effect of systemic HDS on clinical outcome. To calculate the incidence, the total number (187) of patients with metastatic melanoma treated with ipilimumab at Dana-Farber Cancer Institute (DFCI; Boston, MA) was retrieved from the DFCI oncology database. Comparisons between corticosteroid treatment groups were performed using the Fisher exact test. The distributions of overall survival were based on the method of Kaplan–Meier.

Results: The overall incidence of ipilimumab-related hypophysitis was 13%, with a higher rate in males (16.1%) than females

(8.7%). The median time to onset of hypophysitis after initiation of ipilimumab treatment was 9 weeks (range, 5–36 weeks). Resolution of pituitary enlargement, secondary adrenal insufficiency, secondary hypothyroidism, male secondary hypogonadism, and hyponatremia occurred in 73%, 0%, 64%, 45%, and 92% of patients, respectively. Systemic HDS treatment did not improve the outcome of hypophysitis as measured by resolution frequency and time to resolution. One-year overall survival in the cohort of patients was 83%, and while it was slightly higher in patients who did not receive HDS, there was no statistically significant difference between treatment arms.

Conclusion: Systemic HDS therapy in patients with ipilimumab-related hypophysitis may not be indicated. Instead, supportive treatment of hypophysitis-related hormone deficiencies with the corresponding hormone replacement should be given. *Clin Cancer Res*; 21(4); 749–55. ©2014 AACR.

Introduction

CTLA-4 is an immune checkpoint protein that negatively regulates T-cell responses (1). In clinical trials, monoclonal antibodies against immune checkpoint proteins have demonstrated promising and durable anticancer effects (2–4). In 2011, the FDA approved ipilimumab, a humanized monoclonal antibody against CTLA-4, for the treatment of advanced melanoma. Ipilimumab-associated hypophysitis, the most common endocrinopathy related to anti-CTLA-4 treatment, presents as either pan-hypopituitarism or isolated anterior pituitary hormone deficiency, with or without pituitary enlargement (5–8). Systemic high-dose corticosteroids (HDS) have been recommended as a standard treatment for patients with ipilimumab-related hypophysitis

(9, 10), but the benefits of this treatment are unclear. Some studies have suggested that systemic HDS do not appear to counteract the anticancer effects of ipilimumab (11, 12), although this has been questioned in another study (13). To the best of our knowledge, there has been no study assessing the effects of HDS on the outcome of ipilimumab-related hypophysitis. In this retrospective study, we did not identify a beneficial effect of systemic HDS treatment in patients with ipilimumab-related hypophysitis.

Patients and Methods

Patients

Patients with ipilimumab-related hypophysitis were evaluated clinically in the outpatient endocrinology clinic of Brigham and Women's Hospital (Boston, MA). This cohort analysis was performed retrospectively by collecting relevant data from chart reviews. The period for this study was from August 21, 2008 to February 5, 2014. Institutional review board approval was obtained for the study. There were 45 patients who developed ipilimumab-related endocrinopathies after ipilimumab therapy. To eliminate confounding influences from combined therapy, we excluded patients who also received other immune checkpoint blocking therapy, including anti-PD1 (pembrolizumab or nivolumab) or anti-PDL1 (MPDL-3280A), or the angiogenesis inhibitor, bevacizumab. Twenty-five patients with hypophysitis who received ipilimumab monotherapy were included in this analysis.

¹Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts. ²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ³Melanoma and Developmental Therapeutics Clinics, University of Chicago, Chicago, Illinois.

Corresponding Author: Le Min, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115. Phone: 617-732-5666; Fax: 617-732-5764; E-mail: lmin1@partners.org

doi: 10.1158/1078-0432.CCR-14-2353

©2014 American Association for Cancer Research.

Translational Relevance

Ipilimumab, a monoclonal antibody against CTLA-4, has demonstrated promising and durable anticancer effects. Consistent with its mechanism of action of *de novo* stimulation or enhancement of preexisting T-cell responses, a number of immune-related adverse events (irAE) have been observed in patients treated with ipilimumab. Systemic high-dose corticosteroids (HDS) have been routinely used to manage irAEs. However, the cross-talk between glucocorticoid receptor activation and CTLA-4 inhibition remains to be elucidated. We studied the onset and outcome of ipilimumab-related hypophysitis and the response to treatment with systemic HDS. We did not find any beneficial effect of HDS on the outcome of hypophysitis and the malignancy. Our study implies that cross-talk between CTLA-4 inhibition and glucocorticoid receptor activation is a complex process that produces complicated effects on the clinical outcome of CTLA-4 inhibition therapy. Systemic HDS therapy in patients with ipilimumab-related hypophysitis may not be indicated.

Three of these 25 patients were reported previously (6). All patients had stage IV melanoma except for two with stage IIIA and stage IIIC melanoma. To calculate the incidence of hypophysitis, the total number of patients who received ipilimumab monotherapy during the study period was obtained from the Dana-Farber Cancer Institute (Boston, MA) synergistic patient and research knowledge systems-oncology data retrieval system.

Definition of hypophysitis

Hypophysitis was diagnosed on the basis of either imaging evidence of pituitary enlargement or biochemical evidence of anterior pituitary hormone deficiency following ipilimumab treatment. Anterior pituitary hormone deficiencies were diagnosed on the basis of low levels of the primary target gland hormones, cortisol, thyroxine, sex steroids, and insulin—like growth factor I (IGF1), with low or inappropriately normal levels of the corresponding pituitary hormones, adrenocorticotropin (ACTH), thyrotropin (TSH), gonadotropins (FSH, LH), and growth hormone (GH), based on laboratory reference ranges. Endocrinopathy in this study was defined as any of the hypophysitis-related anterior pituitary hormone deficiencies.

Definition of replacement dose corticosteroids, systemic high-dose corticosteroids, time to onset, time to resolution, and survival time

Time to onset of hypophysitis was defined as the number of weeks between the administration of the first dose of ipilimumab and the diagnosis of hypophysitis, based on imaging or biochemical testing. Resolution of a particular endocrinopathy was defined as normalization of levels of the primary target gland hormone and the corresponding pituitary hormone following discontinuation of hormone replacement. The time to resolution refers to the number of weeks between the diagnosis and resolution of the endocrinopathy. Because this was a retrospective study, biochemical testing and imaging were not done at fixed, controlled intervals. Replacement dose corticosteroids were defined as a daily dose not higher than 30 mg hydrocortisone or equivalent (14),

except in 2 patients who were transiently exposed to 60 mg hydrocortisone for 2 to 3 days following sick-day guidelines. Systemic HDS treatment was defined as the administration of corticosteroids at a dose of more than 30 mg hydrocortisone (or equivalent) daily for more than one week during the course of ipilimumab treatment and/or at the time of onset of hypophysitis. Survival time was calculated from the day of initiation of ipilimumab therapy to the day of death of the patient. The follow-up of patients who were alive was censored on February 5, 2014. Toxicity grading of ipilimumab-related hypophysitis was based on the criteria defined by Corsello and colleagues, with modification (15). Briefly, severity was categorized from 1 to 5: 1, asymptomatic; clinical or diagnostic observations only; intervention not indicated. 2, symptomatic; hormone replacement indicated; limiting instrumental activities of daily living (ADL). 3, severe symptoms; limiting self-care for ADL; hospitalization indicated. 4, life-threatening consequences; urgent intervention indicated. 5, death.

Statistical analysis

Statistical analyses are primarily descriptive. Proportions are presented with 95% exact binomial confidence intervals (CI). Comparisons between corticosteroid groups were based on the Fisher exact test. The distributions of overall survival were based on the product-limit method of Kaplan–Meier and were compared using the log-rank test. Time point estimates of survival are accompanied by 95% CIs estimated using log[−log(survival)] methodology. Median follow-up was based on Kaplan–Meier estimates with an inverted censor. Statistical significance was defined as $P < 0.05$. All analyses were conducted using SAS version 9.3.

Results

Demographics

Of 187 patients who received ipilimumab monotherapy during the time interval of the study, 25 patients (13%; 95% CI, 9%–19%) developed ipilimumab-related hypophysitis. Of these 25 patients, 17 received 3 mg/kg ipilimumab and 8 received 10 mg/kg ipilimumab by intravenous infusion every 3 weeks. The incidence of hypophysitis was 16.1% (19/118) in males and 8.7% (6/69) in females (Table 1). Median follow-up in the cohort of patients with hypophysitis was 14.2 months (95% CI, 9.7–18.2 months).

Manifestations of hypophysitis

In light of the retrospective nature of this study, the biochemical tests and imaging performed in individual patients varied. To reflect this variability, the incidence of an endocrinopathy was calculated as the ratio of the number of patients who had abnormal test results over the total number of the patients with ipilimumab-related hypophysitis who had the tests performed. The overall incidence of pituitary enlargement was 60% (15/25)

Table 1. Incidence of ipilimumab-related hypophysitis

	Male	Female	Total
Hypophysitis (N)	19	6	25
Total patients received ipilimumab (N)	118	69	187
Hypophysitis (%)	16.1	8.7	13.3

NOTE: The incidence was calculated as the number of patients with hypophysitis compared with the total number of patients treated with ipilimumab monotherapy.

Table 2. The overall and dose-dependent incidence of ipilimumab-related pituitary enlargement, anterior pituitary hormone deficiencies, and hyponatremia

	Overall			Ipilimumab (3 mg/kg)	Ipilimumab (10 mg/kg)
	Male N = 19	Female N = 6	Total N = 25	Total N = 17	Total N = 8
Pituitary enlargement					
Yes	10 (53)	5 (83)	15 (60)	10 (59)	5 (63)
No	9 (47)	1 (17)	10 (40)	7 (41)	3 (37)
Secondary AI					
Yes	18 (95)	4 (67)	22 (88)	15 (88)	7 (88)
No	1 (5)	2 (33)	3 (12)	2 (12)	1 (12)
Secondary hypothyroidism					
Yes	18 (95)	4 (67)	22 (88)	15 (88)	7 (88)
No	1 (5)	2 (33)	3 (12)	2 (12)	1 (12)
Secondary hypogonadism					
Yes	15 (79)	0 (0)	15 (60)	10 (59)	5 (63)
No	2 (11)	3 (50)	5 (20)	4 (24)	1 (13)
Not measured	2 (11)	3 (50)	5 (20)	3 (18)	2 (25)
Low IGFI					
Yes	3 (60)	0 (0)	3 (12)	1 (33)	2 (50)
No	2 (40)	2 (33)	4 (16)	2 (67)	2 (50)
Not measured	14 (74)	4 (67)	18 (72)	14 (82)	4 (50)
Low prolactin					
Yes	4 (21)	0 (0)	4 (16)	2 (12)	2 (25)
No	4 (21)	1 (17)	5 (20)	2 (12)	3 (38)
Not measured	11 (58)	5 (83)	16 (64)	13 (76)	3 (38)
Hyponatremia					
Yes	12 (63)	2 (33)	14 (56)	10 (59)	3 (38)
No	7 (37)	4 (67)	11 (44)	7 (41)	5 (62)

NOTE: Values are summarized as *N* (%). The incidence of each anterior pituitary hormone deficiency was calculated on the basis of gender and ipilimumab dose, taking into account the number of patients with ipilimumab-related hypophysitis in whom the measure was assessed. The incidence is shown as both the number affected and as a percentage.

Abbreviation: AI, adrenal insufficiency.

among the patients with hypophysitis. Secondary adrenal insufficiency and secondary hypothyroidism were the most common anterior pituitary insufficiencies diagnosed, with an incidence of 88% for each (Table 2). Among the 9 patients who had their prolactin measured, only one had hyperprolactinemia, whereas 4 had low prolactin levels. Only two of the patients with a diagnosis of hypophysitis received corticosteroids within 6 months before the onset of hypophysitis. One of these two patients who had received prior HDS had radiographic evidence of new onset pituitary enlargement. The other patient who had received prior HDS did not have pituitary enlargement on imaging, but the diagnosis of hypophysitis was made on the basis of the presence of rapid onset central hypothyroidism. More than half of the patients with hypophysitis had coexisting hyponatremia, a finding similarly observed in another recent study (9), but not reported in earlier studies (3, 16, 17). When comparing the incidence of each anterior pituitary hormone deficiency between the groups treated with 3 mg/kg and 10 mg/kg ipilimumab, no significant difference in the frequency of each endocrinopathy was found (Table 2).

Patterns of onset and resolution of ipilimumab-related hypophysitis

Given the retrospective nature of this study, the frequency and timing of biochemical tests and imaging performed in individual patients varied, influencing these determinations. With this caveat, the median time to onset of hypophysitis after initiation of ipilimumab therapy, based on diagnostic testing, was 9 weeks, with a range of 5 to 36 weeks (Table 3). The frequency of resolution of secondary adrenal insufficiency, secondary hypothyroidism, and male hypogonadotropic hypogonadism (HH) was 0%, 64%, and 47%, respectively. Among the subset of patients whose endocrinopathy resolved, the median times to resolution of secondary hypothyroidism and male HH, based on biochemical testing, were 10 and 15 weeks, respectively (Table 3). Discontinuation of ipilimumab did not appear to affect the outcome of hypophysitis. In the 6 patients in whom ipilimumab was discontinued, the frequency of resolution of secondary hypothyroidism and secondary hypogonadism was 33% (2/6 and 1/3, respectively). The median times to resolution, based on

Table 3. Median time to onset, frequency of resolution, and median time to resolution

	Time to onset (median wk, range)	Resolution, N (%)	Time to resolution (median wks; range)
Hypophysitis	9 (5–36)		
Pituitary enlargement	8 (5–13)	11 (73.3)	15 (2–27)
Secondary adrenal insufficiency	9.5 (5–36)	0 (0.0)	n/a
Secondary hypothyroidism	9.5 (6–36)	14 (63.6)	10.5 (1–44)
Secondary hypogonadism	9 (5–13)	7 (46.7)	15 (2–92)
Hyponatremia	9 (5–36)	12 (92.3)	3.5 (1–10)

NOTE: Time is measured in weeks. The frequency of resolution is represented as the number of patients in whom resolution occurred, and as a percentage of the patients in whom the deficiency was noted.

Abbreviations: n/a, not available; N, number of patients.

laboratory testing, of secondary hypothyroidism and secondary hypogonadism after discontinuation of ipilimumab among these 6 patients were 13 and 10 weeks, respectively. Most patients in this study received 3 to 4 doses of ipilimumab, whereas 3 patients received 8, 9, and 15 doses of ipilimumab, respectively. Interestingly, among the three patients who had received prolonged ipilimumab therapy, resolution of a subset of endocrinopathies occurred during ipilimumab treatment. Normalization of pituitary size was observed in 11 of 15 patients (73%) with enlarged pituitaries in 2 to 27 weeks, based on follow-up imaging. The other 4 patients did not have repeated imaging studies before the end of this study. Six of 11 patients with resolution of enlarged pituitaries had earlier MRI studies, at 3 to 8 weeks after identification of pituitary enlargement, which did not show resolution of pituitary enlargement.

The effect of HDS therapy on the outcome of ipilimumab-related hypophysitis and on survival rate

Among 25 patients with ipilimumab-related hypophysitis, 15 patients received HDS treatment for ipilimumab-related hypophysitis (*n* = 5), other immune-related adverse events (IrAE; *n* = 8), or brain metastasis (*n* = 2). The patients in the HDS group received dexamethasone (*n* = 4, dose: 4–24 mg daily; duration: 3–12 weeks), prednisone (*n* = 9, dose: 40–100 mg daily; duration: 2–14 weeks), hydrocortisone (*n* = 1; dose: 60 mg daily; duration: 3 weeks), or dexamethasone followed by prednisone (*n* = 1, doses: dexamethasone 8 mg daily; duration: 1 week, prednisone 40 mg daily; duration: 5 weeks). The other 10 patients did not receive HDS during the study period. Among the patients who received HDS, 6 of 15 (40%; 95% CI, 16%–68%) had grade 2 ipilimumab-related hypophysitis toxicity; 9 of 15 (60%; 95% CI, 32%–84%) had grade 3/4 toxicity (17). Among the patients who received replacement corticosteroids, 7 of 10 (70%; 95% CI, 35%–93%) had grade 2 toxicity; 3 of 10 (30%; 95% CI, 7%–65%) had grade 3/4 toxicity. Toxicity rates were comparable between the HDS and non-HDS cohorts.

We compared the frequency of resolution and the median times to resolution, based on laboratory testing data available, between those with and without systemic HDS treatment (Table 4). There was no documented resolution of secondary adrenal insufficiency in either group. Among patients with secondary adrenal insufficiency who received HDS, 13 patients had morning paired ACTH and cortisol levels tested 2 to 12 months after HDS withdrawal. All 13 patients who had adrenal function testing demonstrated persistent adrenal insufficiency. There were no statistically significant differences in the frequency of resolution of other adverse events (Table 4 and Fig. 1), although the data suggest that the frequency of resolution of secondary hypothyroidism may be less in the HDS group (46% versus 89%, Fisher exact *P* = 0.07; Fig. 1).




Figure 1. The effect of HDS on the frequency of resolution of each endocrinopathy. The frequency of resolution is represented as the percentage of those with resolution compared with the total number affected for each endocrinopathy.

In addition, median times to resolution for each adverse event were comparable between the two groups (Table 4).

During the course of the study, 4 of 15 (27%) patients in the HDS treatment group died, whereas one of 10 (10%) patients in the group that did not receive HDS died. Twelve-month Kaplan–Meier estimates (SE) of survival were 83% (7.7%) for the full cohort, and 80% (10.8%) and 89% (10.5%) in patients who did or did not receive HDS, respectively (Fig. 2). All deaths were attributed to the underlying metastatic disease.

Discussion

Although a definitive diagnosis of autoimmune hypophysitis by ipilimumab has not been documented, an animal study has shown that injection of a CTLA-4–blocking antibody can induce lymphocytic infiltration in mouse pituitary glands (18). Non-ipilimumab–related autoimmune hypophysitis is more common in females, with a male:female ratio of 1:6 for lymphocytic adenohypophysitis (19, 20). In contrast, in the current study, the incidence of ipilimumab-related hypophysitis was found to be higher in males (Table 1). Similar results were found in some, but not all, prior studies (8, 15). Ipilimumab-associated diabetes insipidus has been reported (21); nonetheless, compared with anterior pituitary hormone deficiencies, posterior pituitary hormone deficiency is infrequent (5–7). In this retrospective cohort

Table 4. The effect of HDS on the frequency of resolution of ipilimumab-related adverse events


HDS	Resolution (<i>N</i> with resolution/ <i>N</i> affected)		Median time to resolution (Median wk; range)	
	No	Yes	No	Yes
	Pituitary enlargement	5/6	6/9	8 (2–27)
Secondary adrenal insufficiency	0/10	0/12	n/a	n/a
Secondary hypothyroidism	8/9	6/13	14.5 (2–44)	9 (1–16)
Secondary hypogonadism	5/8	2/7	40 (2–92)	12 (10–15)
Hyponatremia	5/5	7/8	2 (1–7)	4 (1–10)

NOTE: The frequency of resolution is calculated as the number with resolution compared with the total number affected for each endocrinopathy. The time is measured in weeks.

Abbreviations: *N*, number; n/a, not applicable.

Downloaded from http://aacrjournals.org/clinccancerres/article-pdf/21/4/749/2028141749.pdf by guest on 27 March 2025

Figure 2.
The effects of HDS on survival rate.
Kaplan-Meier estimates of overall survival with the numbers of patients at risk. The x-axis was extended to 32 months (median follow-up + 18 months), the time at which there was 20% or less of the sample remaining.



analysis, even in one patient with transient prolactin elevation suggestive of possible pituitary stalk infiltration, there was no evidence of diabetes insipidus.

The risk of hypopituitarism in patients receiving brain radiation has been documented (22). In the current study, 2 patients diagnosed with hypophysitis on the basis of pituitary insufficiency but without pituitary enlargement had received brain radiation therapy before the diagnosis of hypophysitis. One developed reversible central hypothyroidism, whereas radiation-induced hypopituitarism is usually irreversible (23). Another developed rapid onset of secondary adrenal insufficiency following ipilimumab therapy. His growth hormone and gonadal axes remained intact. Because corticotrophs are the most resistant to radiation damage (22, 23), the normal growth hormone and gonadal axes combined with severe ACTH deficiency make radiation-induced isolated ACTH deficiency unlikely. For these reasons, it was concluded that brain radiation was not the cause of the hypopituitarism in these 2 patients.

Pituitary enlargement is one of the major concerns in these patients, because the enlarged pituitary may compress the optic chiasm and cause visual field deficits. In very rare cases, inflammation associated with autoimmune hypophysitis (non-ipilimumab-related) was reported to extend to the cavernous sinus and result in progressive internal carotid artery stenosis as well as rapid visual deterioration (24). In the current and in another recent study (7), no patient had radiographic evidence of optic nerve compression or cavernous sinus extension. All patients had gross visual field examinations and some ($n = 4$) had formal visual field testing; none had hypophysitis-related visual field deficits. The lack of pituitary imaging before ipilimumab therapy and variable intervals between radiographic studies in some patients may have underestimated the incidence of pituitary enlargement, because transient and mild pituitary enlargement may occur in some

patients (7). In this study, most of the enlarged pituitaries normalized in size in serial radiographic studies, in both corticosteroid replacement and HDS groups.

Although the mechanisms are not known, it appears that corticotrophs and thyrotrophs are more vulnerable to ipilimumab-related damage than other anterior pituitary cells, because ACTH and TSH deficiencies were most commonly seen in these patients (Table 2). The recovery of corticotroph function appears to be rare because resolution of secondary adrenal insufficiency was not observed in this study and was infrequently reported in previous studies (7, 8, 11). The median time to onset of pituitary enlargement was one week earlier than that of biochemical evidence of pituitary hormone deficiency. This finding, consistent with another recent report (7), is important because the first manifestation of hypophysitis in patients on ipilimumab therapy could be the incidental finding of an enlarged pituitary gland during surveillance or restaging brain MRI scan, without initial biochemical evidence of pituitary hormone deficiency. Because secondary adrenal insufficiency, which can be life threatening, occurs in almost every patient with ipilimumab-related hypophysitis, we recommend starting these patients on replacement doses of corticosteroids proactively, even if their initial biochemical tests show normal cortisol levels. Hyponatremia occurred concomitantly with hypophysitis, suggesting a close relationship between these two conditions.

In the ipilimumab package insert, as well as in the literature, a course of HDS is the recommended treatment for patients with ipilimumab-related hypophysitis. However, there have been no compelling data to support this management approach. Similarly, although HDSs are commonly used in classic autoimmune hypophysitis in an attempt to reduce inflammation, reduce mass effect symptoms related to the enlarged pituitary, and prevent or reverse pituitary hormone deficiency, the outcomes have been variable

(19, 25). In the present study, among 10 patients who did not receive HDS treatment, replacement doses of corticosteroids substantially improved headaches and fatigue. The frequency of resolution and time to resolution did not significantly differ between the groups that did and did not receive HDS (Table 4 and Fig. 1). Differences in the severity of hypophysitis cannot account for this finding because the average toxicity score for the severity of hypophysitis was not different between the two groups. In the case of secondary adrenal insufficiency, no recovery was identified among our patient cohort, regardless of whether they were treated with systemic HDS or not. It is not clear whether persistent adrenal insufficiency after HDS withdrawal was due to hypophysitis, adrenal suppression from HDS (26), or both. In any case, HDS did not improve the recovery of corticotroph function. On the basis of these findings, we conclude that systemic HDS treatment did not improve the outcome of ipilimumab-related hypophysitis.

As a result of its immunosuppressant activity, the potential effects of corticosteroids on the anticancer activity of immune checkpoint inhibition must be taken into consideration. In a previous study, the median duration of response was somewhat shorter in patients who received systemic HDS, although there was no statistically significant effect on the overall duration of clinical response (11). In the present study, we observed an 83% one-year survival rate in the full cohort, which surpasses survival rates reported in previously published trials of ipilimumab (3, 27). A higher rate of mortality was observed in the group treated with HDS; however, the distributions of overall survival were not statistically significantly different between groups (Fig. 2). The survival outcomes of our study concur with those of previous studies (11, 13), which have questioned the null effect of HDS on survival outcome. On the basis of the outcome of this study (albeit retrospective), we recommend initiation of hormone

replacement without routine systemic HDS in patients with ipilimumab-related hypophysitis. Our study is limited by its retrospective nature, limited size, and variability of the timing of initial and subsequent hormonal and radiographic evaluation.

Disclosure of Potential Conflicts of Interest

L. Min is a consultant/advisory board member for Merck. F.S. Hodi reports receiving a commercial research grant from and is a consultant/advisory board member for Bristol-Myers Squibb. P.A. Ott is a consultant/advisory board member for Bristol-Myers Squibb. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: L. Min, F.S. Hodi, R.S. Carroll, U.B. Kaiser

Development of methodology: L. Min, F.S. Hodi, U.B. Kaiser

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L. Min, F.S. Hodi, P.A. Ott, J.J. Luke, H. Donahue, M. Davis

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L. Min, F.S. Hodi, A. Giobbie-Hurder, J.J. Luke, U.B. Kaiser

Writing, review, and/or revision of the manuscript: L. Min, F.S. Hodi, A. Giobbie-Hurder, P.A. Ott, J.J. Luke, M. Davis, R.S. Carroll, U.B. Kaiser

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L. Min, F.S. Hodi, P.A. Ott

Study supervision: U.B. Kaiser

Grant Support

This work was supported by NICHD/NIH K08 HD070957 (to L. Min).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 9, 2014; revised December 1, 2014; accepted December 15, 2014; published OnlineFirst December 23, 2014.

References

- Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. *Annu Rev Immunol* 2001;19:565-94.
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443-54.
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711-23.
- Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N Engl J Med* 2013;369:134-44.
- Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockade can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. *J Immunother* 2005;28:593-8.
- Min L, Vaidya A, Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. *Endocr Pract* 2012;18:351-5.
- Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. *J Clin Endocrinol Metab* 2014;99:4078-85.
- Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. *Endocr Relat Cancer* 2014;21:371-81.
- Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. *Am Soc Clin Oncol Educ Book* 2012;32:174-7.
- Corsello SM, Salvatori R, Barnabei A, De Vecchis L, Marchetti P, Torino F. Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). *Cancer Chemother Pharmacol* 2013;72:489-90.
- Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. *Clin Cancer Res* 2007;13:6681-8.
- Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. *J Clin Oncol* 2006;24:2283-9.
- Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. *Lancet Oncol* 2012;13:459-65.
- Johannsson G, Falorni A, Skrtic S, Lennernas H, Quinkler M, Monson JP, et al. Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. *Clin Endocrinol* 2014 Sep 4. [Epub ahead of print].
- Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. *J Clin Endocrinol Metab* 2013;98:1361-75.
- Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. *Cancer* 2013;119:1675-82.

17. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. *Pituitary* 2009;13:29–38.
18. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. *Sci Transl Med* 2014;6:230ra45.
19. Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR. Autoimmune hypophysitis. *Endocr Rev* 2005;26:599–614.
20. Hamnvik OP, Laury AR, Laws ER Jr, Kaiser UB. Lymphocytic hypophysitis with diabetes insipidus in a young man. *Nat Rev Endocrinol* 2010;6:464–70.
21. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. *J Clin Oncol* 2012;30:2691–7.
22. Fernandez A, Brada M, Zabuliene L, Karavitaki N, Wass JA. Radiation-induced hypopituitarism. *Endocr Relat Cancer* 2009;16:733–72.
23. Darzy KH. Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. *Nat Clin Pract Endocrinol Metab* 2009;5:88–99.
24. Buxton N, Robertson I. Lymphocytic and granulocytic hypophysitis: a single centre experience. *Br J Neurosurg* 2001;15:242–5.
25. Kristof RA, Van Roost D, Klingmuller D, Springer W, Schramm J. Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy? *J Neurol Neurosurg Psychiatry* 1999;67:398–402.
26. Dinsen S, Baslund B, Klose M, Rasmussen AK, Friis-Hansen L, Hilsted L, et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. *Eur J Intern Med* 2013;24:714–20.
27. Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. *JAMA* 2014;312:1744–53.